Abstract: The pathophysiological mechanism of psoriasis involves a polygenic genetic background and an imbalance in the immune regulatory network. The activation of the IL-23/IL-17 inflammatory axis mediated by Th17 cells is considered a key driver of plaque psoriasis. Abnormalities in the IL-36 pathway are closely associated with acute exacerbations of generalized pustular psoriasis. Biological agents related to these pathways have become important options for the treatment of psoriasis. This paper reviews the progress in the treatment of childhood plaque psoriasis and generalized pustular psoriasis with biological agents.

Key words: biologics, plaque psoriasis, generalized pustular psoriasis, children